Armstrong, A. J., Appleman, L. J., Danila, D. C., Lin, C.-C., Lee, J. L., Matsubara, N., … Kelly, W. K. (2024). 1610P Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig. In Annals of Oncology (Vol. 35, pp. S971–S972). Elsevier BV. https://doi.org/10.1016/j.annonc.2024.08.1691

Armstrong, A. J., L. J. Appleman, D. C. Danila, C. -. C. Lin, J. L. Lee, N. Matsubara, P. J. Ward, et al. “1610P Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig.” In Annals of Oncology, 35:S971–72. Elsevier BV, 2024. https://doi.org/10.1016/j.annonc.2024.08.1691.

Armstrong AJ, Appleman LJ, Danila DC, Lin C-C, Lee JL, Matsubara N, et al. 1610P Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig. In: Annals of Oncology. Elsevier BV; 2024. p. S971–2.

Armstrong, A. J., et al. “1610P Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig.” Annals of Oncology, vol. 35, Elsevier BV, 2024, pp. S971–72. Crossref, doi:10.1016/j.annonc.2024.08.1691.

Armstrong AJ, Appleman LJ, Danila DC, Lin C-C, Lee JL, Matsubara N, Ward PJ, Pook DW, Kim M, Dorff TB, Fischer SC, Lin Y-C, Horvath LG, Sumey C, Yang Z, Decato BE, Englert JM, Smith KM, Lolkema M, Kelly WK. 1610P Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig. Annals of Oncology. Elsevier BV; 2024. p. S971–S972.